Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122

Prostate cancer (PCa) is a common aggressive disease worldwide which usually progresses into incurable castration-resistant prostate cancer (CRPC) in most cases after 18–24 months treatment. Androgen receptor (AR) has been considered as a crucial factor involved in CRPC and the study of AR as a pote...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Cong, Xiaonan, He, Yundong, Wu, Haigang, Wang, Dingxiang, Liu, Yongrui, Shao, Ting, Liu, Mingyao, Yi, Zhengfang, Zheng, Jianghua, Peng, Shihong, Ding, Tao
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8210671/
https://ncbi.nlm.nih.gov/pubmed/34150618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.650919
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars